Get started
Author

Nusaïbah Ibrahimi

Observed names: Ibrahimi, Nusaibah, Ibrahimi, Nusaïbah, N. Ibrahimi, Nusaibah Ibrahimi
ORCID: 0000-0003-4537-0323
Observed ORCID: 0000-0003-4537-0323
OpenAlex ID: A5016155985
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer
2022 · Marta Palafox, Laia Monserrat, et al. · Nature Communications · 140
PDF
Screening for SARS-CoV-2 by RT-PCR: Saliva or nasopharyngeal swab? Rapid review and meta-analysis
2021 · Nusaïbah Ibrahimi, Agnès Delaunay-Moisan, et al. · PLoS ONE · 47
PDF
Delivering adapted physical activity by videoconference to patients with fatigue under immune checkpoint inhibitors: Lessons learned from the PACTIMe-FEAS feasibility study
2021 · Cécile Charles, Aurélie Bardet, et al. · Journal of Telemedicine and Telecare · 33
PDF
Dynamics of circulating calprotectin accurately predict the outcome of moderate COVID-19 patients
2022 · Nicolas Chapuis, Nusaibah Ibrahimi, et al. · EBioMedicine · 29
PDF
189O A phase II study of patritumab deruxtecan (HER3-DXd), in patients (pts) with advanced breast cancer (ABC), with biomarker analysis to characterize response to therapy (ICARUS-BREAST01)
2023 · B. Pistilli, N. Ibrahimi, et al. · ESMO Open · 19
PDF
Severe COVID-19 in patients with hematological cancers presenting with viremia
2021 · J.M. Michot, T. Hueso, et al. · Annals of Oncology · 15
Outcomes of Patients With Active Cancer and COVID-19 in the Intensive-Care Unit: A Multicenter Ambispective Study
2022 · Henri Plais, Marie Labruyère, et al. · Frontiers in Oncology · 11
Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer
2022 · Marta Palafox, Laia Monserrat, et al. · Nature Communications · 7
PDF
Abstract 2104: Epigenetic, transcriptomic and genetic analyses of HR+/HER2- primary and metastatic breast cancer results in cohort stratification by aggressiveness and reveals heterogeneous mechanisms of endocrine therapy resistance
2025 · Jomar Sangalang, Tony Sourisseau, et al. · Cancer Research · 1
Abstract 6613: Triple-negative breast cancer evolution and therapy response: Breast TRACERx
2025 · Ieva Usaite, Thomas B. Watkins, et al. · Cancer Research · 1
Building a Standardised Statistical Reporting Toolbox in an Academic Oncology Clinical Trials Unit: The grstat R Package
2026 · Chaltiel, Dan, Cochard, Alexis, et al. · arXiv (Cornell University)
PDF
Phase 2 Nivo-alcl Study of Nivolumab for Relapse/refractory Alk+alcl, for Patients With Progressive Disease or as Consolidative Immunotherapy After Complete Remission
2025 · Charlotte Rigaud, Nusaibah Ibrahimi, et al. · Leukemia Research
Short-term pre-operative durvalumab (MEDI 4736) in early small triple-negative breast cancer patients (POP-Durva).
2025 · Joana M. Ribeiro, Julia Dixon-Douglas, et al. · Journal of Clinical Oncology
25TiP Short-term pre-operative durvalumab in early small triple negative breast cancer patients (POP-Durva)
2024 · J.R. Dixon Douglas, J.T.M.L. Ribeiro, et al. · Annals of Oncology
PDF
LBA4 Dynamic immune compartment remodeling in response to durvalumab in the POP-DURVA study: Comprehensive Profiling using spectral cytometry and multiplex immunohistochemistry
2024 · J.T.M.L. Ribeiro, I. Pic, et al. · Immuno-Oncology Technology
PDF
112MO Triple-negative breast cancer evolution and therapy response: Breast TRACERx
2024 · I. Usaite, O. Lucas, et al. · ESMO Open
PDF
Abstract PO2-18-11: Short-term Pre-OPerative Durvalumab (MEDI 4736) in early small triple negative breast cancer patients (POP-Durva)
2024 · Joana Mourato Ribeiro, Isabelle Pic, et al. · Cancer Research
[Covid-19 vaccines available in Europe. New data].
2021 · Nusaïbah Ibrahimi, Dan Chaltiel, et al. · PubMed
1639P Impact of COVID-19 on ongoing oncological and hematological treatment strategy
2021 · A. Bayle, K. Ouali, et al. · Annals of Oncology
PDF
["Covid-19 vaccines available in March 2021"].
2021 · Nusaïbah Ibrahimi, Dan Chaltiel, et al. · PubMed
Screening for SARS-CoV-2 by RT-PCR: Saliva or Nasopharyngeal Swab? Systematic Review and Meta-Analysis
2021 · Nusaïbah Ibrahimi, Agnès Delaunay-Moisan, et al. · SSRN Electronic Journal
Works count: 22
Citation count: 303
H-index: 7
I10-index: 7
Year
Topic
Type